Guidelinehigh evidence
Deprescribing in Patients With Cardiovascular Disease Experiencing Polypharmacy: A Scientific Statement From the American Heart Association.
Circulation·July 8, 2026·PMID 42417036
Why it mattersPolypharmacy is common in cardiovascular patients and contributes to adverse outcomes, yet guidance on deprescribing has been limited. This statement offers a structured, evidence-informed framework to help clinicians identify and reduce inappropriate medications, potentially improving safety and outcomes.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled